In epithelial ovarian cancer, inhibiting DYRK1A via siRNA knockdown or CDK inhibition compromised the DREAM complex and enhanced the viability of ovarian cancer cell spheroids [25]. This evidence concerns the gene DYRK1A and ovarian carcinoma.